Phase 3 Readout

CRDF: Phase 3 Topline: A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Versus Pl

Name: Phase 3 Topline: A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Versus Pl
Start: 2032-10-01
End: 2032-10-01

October 1, 2032 · zipalertinib. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: October 1, 2032
Company: Cardiff Oncology, Inc. (CRDF)
Drug: zipalertinib

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Versus Pl

October 1, 2032

CRDF overview →

Company: Cardiff Oncology, Inc. (CRDF)
Drug: zipalertinib
Indication: Lung Cancer; EGFR; Adjuvant